GlassScriptPhysician profile
Andrew S Crawford
NPI 1447237938
$7,894.20
in general payments reported to CMS, 2019-2025
38 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $979 · 2021: $1,750 · 2022: $993 · 2023: $1,051 · 2024: $955 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.14 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,084.08 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $738.19 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $516.48 | 2019-2025 | |
| Gilead Sciences, INC. | $509.87 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.44 | 2019-2022 | |
| Medtronic, INC. | $375.40 | 2021-2024 | Gi Genius, Nexpowder |
| Boston Scientific Corporation | $235.97 | 2019-2025 | Captivator II, Watchman Access System, Watchman Flx |
| Olympus America INC. | $221.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.90 | 2019-2022 | |
| Histosonics, INC. | $154.27 | 2025 | |
| Genzyme Corporation | $152.65 | 2022-2025 | |
| Qol Medical, LLC | $122.99 | 2020-2025 | Sucraid |
| Celgene Corporation | $121.54 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $120.41 | 2021 | |
| Janssen Scientific Affairs, LLC | $96.41 | 2024 | Tremfya |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $93.14 | 2019-2020 | |
| Novo Nordisk INC | $91.66 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $67.60 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $66.56 | 2020-2025 | |
| Lilly USA, LLC | $49.46 | 2025 | Omvoh |
| Redhill Biopharma INC. | $39.37 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $38.32 | 2022-2025 | Terlivaz |
| Daiichi Sankyo INC. | $38.23 | 2021 | |
| Amag Pharmaceuticals, INC. | $36.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $33.70 | 2019 | |
| Ironwood Pharmaceuticals, INC | $30.40 | 2020 | |
| Ambu INC. | $27.61 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.53 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $24.50 | 2021 | |
| Astellas Pharma US INC | $24.18 | 2023 | |
| Celltrion USA INC. | $22.75 | 2025 | Vegzelma |
| Sobi, INC | $19.50 | 2022 | |
| Aimmune Therapeutics, INC. | $18.96 | 2024 | |
| Amgen INC. | $18.64 | 2023 | Amjevita, Avsola |
| Ethicon US, LLC | $18.32 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.16 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.45 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.